Piperazin-2-one → 1-methyl-6-{4-[3-(3-oxo-piperazin-1-yl)-propyl]-3-trifluoromethyl-phenyl}-1H-imidazo[4,5-c]pyridine-4-carbonitrile
反応式
Br[CH2:2][CH2:3][CH2:4][C:5]1[CH:10]=[CH:9][C:8]([C:11]2[N:16]=[C:15]([C:17]#[N:18])[C:14]3[N:19]=[CH:20][N:21]([CH3:22])[C:13]=3[CH:12]=2)=[CH:7][C:6]=1[C:23]([F:26])([F:25])[F:24].[O:27]=[C:28]1[CH2:33][NH:32][CH2:31][CH2:30][NH:29]1>CN(C=O)C>[CH3:22][N:21]1[C:13]2[CH:12]=[C:11]([C:8]3[CH:9]=[CH:10][C:5]([CH2:4][CH2:3][CH2:2][N:32]4[CH2:31][CH2:30][NH:29][C:28](=[O:27])[CH2:33]4)=[C:6]([C:23]([F:26])([F:25])[F:24])[CH:7]=3)[N:16]=[C:15]([C:17]#[N:18])[C:14]=2[N:19]=[CH:20]1参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
6-(4-(3-Bromopropyl)-3-(trifluoromethyl)-phenyl)-1-methyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile (50 mg) and 2-oxopiperazine (103 mg) in DMF (750 μl) were heated at 100° C. in a microwave for 25 minutes. Purification by basic phase preparative LCMS afforded 1-methyl-6-{4-[3-(3-oxo-piperazin-1-yl)-propyl]-3-trifluoromethyl-phenyl}-1H-imidazo[4,5-c]pyridine-4-carbonitrile (15 mg).
後処理
- customPurification by basic phase preparative LCMS
出典と根拠
- ORDレコード
- ord-e3152451a5b8465ebf5becdaf01fb6b6
- 出典データセット
- uspto-grants-2011_04
- 特許番号
- US07932251B2
反応ノート
読み込み中…